VolitionRx Initiates $25 Million At-the-Market Offering

VolitionRx Limited initiated a $25 Million At-the-Market Offering pursuant to its existing Shelf Registration Statement on Form S-3, with Jefferies LLC acting as sales agent.

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.